PubMed Health⌕ Search

Biomedical subjects

Pedro Jaén

Publications and source records attributed to Pedro Jaén.

5 recordsLinked to original sources

[Gefitinib-induced perforating dermatosis].

Gefitinib (Iressa) is a new antineoplastic agent that acts by selectively inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). It has shown activity against several solid tumors. Because of their action mechanism, gefitinib and other tyrosine kinase inhibitors have been associated with multiple cutaneous effects, most of which are mild and well tolerated. We present a case of perforating dermatosis after treatment with gefitinib.

Antineoplastic Agents↗

[Blastic NK-cell lymphoma].

Blastic NK (< >) cell lymphoma is a rare type of lymphoma, recognized as an independent entity in the new World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification for cutaneous lymphomas. Its clinical, morphological and immunophenotypical characteristics are relatively well defined. It frequently starts with extranodal involvement (primarily cutaneous), often presents with splenomegaly and pancytopenia, and initially responds well to chemotherapy, although the medium-term prognosis is usually poor. It was first considered to originate from immature NK lymphocytes, but now its origin is thought to be plasmacytoid dendritic cell precursors. We present the clinicopathological characteristics of a new case of this entity in a 78-year-old male patient.

Aged↗

[Herpes simplex prophylaxis in facial exfoliation treatments].

In recent years, a spectacular increase has taken place in the demand for techniques to improve the appearance of the skin, both for cosmetic and reparative purposes. The techniques used may have complications that interfere with the healing process, and therefore may affect the results from an aesthetic standpoint. The most significant complication is herpes simplex infection. Furthermore, accurate, early diagnosis of herpes infection makes greater individual and community control possible, thanks to the current availability of effective antiviral agents. The scientific literature relating to herpes simplex prophylaxis was reviewed, and this information was pooled with the knowledge and experience of a multidisciplinary group of experts. After all of this data was analyzed, the consensus was reached that all patients should be treated with specific oral medications for herpes simplex as a preventive measure.

Contraindications↗